The CDC is recommending the Pfizer-BioNTech and Moderna COVID-19 vaccines over Janssen’s, due to 57 cases of a rare blood clotting condition.
Last night, the US Centers for Disease Control and Prevention (CDC)
While the CDC still recommends the Janssen shot if no other vaccines are available, 57 cases of rare blood clotting led the CDC to promote the mRNA vaccines over Janssen’s.
The condition, thrombosis with thrombocytopenia syndrome (TTS), is indicated by blood clots and low blood platelet levels. Of the 57 cases, most occurred in women 18-49 years old, and 36 required treatment in intensive care units.
Since April 2021, the rate of TTS has slowly increased to 3.8 per million doses administered. While the condition remains rare, there have been 9 reported deaths so far, 7 in women and 2 in men.
The updated recommendation comes unanimously from the CDC’s Advisory Committee on Immunization Practices (ACIP) panel, which the CDC opted to endorse.
Due to the US’s optimal supply of mRNA vaccines, the Janssen vaccine is no longer needed as a first resort. However, ACIP continued to assert that “receiving any vaccine is better than being unvaccinated. Individuals who are unable or unwilling to receive an mRNA vaccine will continue to have access to Johnson & Johnson’s COVID-19 vaccine.”
Approximately 16.9 million Americans received a dose of the Janssen vaccine. Because the initial regimen only consists of 1 dose, as opposed to 2 shots for the mRNA vaccines, the Janssen vaccine was widely rolled out among populations for whom receiving a multi-dose series would prove more difficult, such as low-income people or people experiencing homelessness.
The CDC
“More than 200 million Americans have completed their primary vaccine series, providing protection against COVID-19, preventing millions of cases and hospitalizations, and saving over a million lives…I continue to encourage all Americans to get vaccinated and boosted," CDC Director Dr. Rochelle Walensky said.
